全文获取类型
收费全文 | 295814篇 |
免费 | 23323篇 |
国内免费 | 10431篇 |
专业分类
耳鼻咽喉 | 5980篇 |
儿科学 | 4205篇 |
妇产科学 | 5273篇 |
基础医学 | 29496篇 |
口腔科学 | 6484篇 |
临床医学 | 29928篇 |
内科学 | 33369篇 |
皮肤病学 | 2503篇 |
神经病学 | 10379篇 |
特种医学 | 9271篇 |
外国民族医学 | 90篇 |
外科学 | 53771篇 |
综合类 | 45782篇 |
现状与发展 | 20篇 |
一般理论 | 27篇 |
预防医学 | 15411篇 |
眼科学 | 8362篇 |
药学 | 22844篇 |
200篇 | |
中国医学 | 8945篇 |
肿瘤学 | 37228篇 |
出版年
2024年 | 766篇 |
2023年 | 4633篇 |
2022年 | 8668篇 |
2021年 | 11535篇 |
2020年 | 10685篇 |
2019年 | 9963篇 |
2018年 | 9578篇 |
2017年 | 9344篇 |
2016年 | 10005篇 |
2015年 | 9994篇 |
2014年 | 17657篇 |
2013年 | 17659篇 |
2012年 | 16231篇 |
2011年 | 18069篇 |
2010年 | 15355篇 |
2009年 | 14920篇 |
2008年 | 14683篇 |
2007年 | 15894篇 |
2006年 | 14508篇 |
2005年 | 13851篇 |
2004年 | 11825篇 |
2003年 | 10221篇 |
2002年 | 8022篇 |
2001年 | 7845篇 |
2000年 | 6525篇 |
1999年 | 5735篇 |
1998年 | 4322篇 |
1997年 | 3875篇 |
1996年 | 3445篇 |
1995年 | 3206篇 |
1994年 | 2796篇 |
1993年 | 2317篇 |
1992年 | 1981篇 |
1991年 | 1743篇 |
1990年 | 1422篇 |
1989年 | 1335篇 |
1988年 | 1273篇 |
1987年 | 1032篇 |
1986年 | 797篇 |
1985年 | 876篇 |
1984年 | 855篇 |
1983年 | 535篇 |
1982年 | 656篇 |
1981年 | 566篇 |
1980年 | 479篇 |
1979年 | 368篇 |
1978年 | 311篇 |
1977年 | 248篇 |
1976年 | 270篇 |
1975年 | 175篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
直肠癌切除前后腹腔冲洗液脱落细胞学对比研究 总被引:1,自引:0,他引:1
目的研究直肠癌术中腹腔多次冲洗,对于降低患者腹腔内脱落癌细胞阳性率的临床意义。方法对63例直肠癌患者术中腹腔冲洗分6次进行,肿瘤切除前3次,切除后3次;将6次腹腔冲洗液行常规病理学涂片细胞学检查结果进行对比。结果肿瘤切除前,全组患者腹腔冲洗液脱落癌细胞均呈阳性表达。肿瘤切除后第1次腹腔冲洗液脱落癌细胞阳性40例,第2次阳性33例,第3次阳性13例。肿瘤切除后第1次冲洗液的脱落癌细胞阳性结果与切除后第2次冲洗液阳性结果比较,P〉0.05,差异无统计学意义;但第3次冲洗液的脱落癌细胞阳性结果与第2次比较,P〈0.01,差异有统计学意义。结论对直肠癌患者进行术中多次腹腔冲洗可降低腹腔内脱落癌细胞的阳性率。 相似文献
32.
目的评价牙冠延长术在牙体缺损达龈下的残根残冠修复中的临床疗效。方法自2004年5月至2005年6月,对32例患者的36颗牙体缺损达龈下的患牙,术前按断端位于龈下最深距离分为A组(20颗患牙,距离<3.0mm)和B组(16颗患牙,3.0mm≤距离≤4.0mm),均采用牙冠延长术暴露龈下牙体断面,术后6周行桩冠修复。分别记录和比较手术前、后牙周探诊深度(PD)、菌斑指数(PLI)、龈沟出血指数(SBI)和牙齿松动度,以观察临床疗效。结果术后随访患者6个月,两组病例术后6周牙体断端均暴露较好、龈缘颜色正常,术后修复效果有效率为100%,满意率为77.78%。A组术后无松动,修复效果满意;B组术后50.00%出现Ⅰ度松动,修复效果欠佳,两组修复效果比较差异有显著意义(P<0.05)。术后各阶段两组的PD、PLI、SBI均明显优于术前(P<0.05),但两组术后牙周指数比较差异无显著意义(P>0.05)。结论牙冠延长术有利于残根残冠的保存和修复,但要注意适应证的选择。 相似文献
33.
Palat Balachandran M.S. M.Ch. Shaleen Agarwal M.S. M.Ch. Narendra Krishnani M.D. Chandra M. Pandey Ph.D. Ashok Kumar M.S. M.Ch. Sadiq S. Sikora M.S. Rajan Saxena M.S. Vinay K. Kapoor M.S. 《Journal of gastrointestinal surgery》2006,10(6):848-854
The aim of this study was to examine the predictors of long-term survival (>24 months) in patients with gall bladder cancer.
A retrospective review of 117 cases of gall bladder cancer resected between 1989 and 2000. The resections included 80 simple
cholecystectomies and 37 extended procedures. Patients with survival >24 months (n=44) were compared with those having survival
<24 months (n=73) for 17 prognostic factors. Overall median survival was 16 months with a 5-year survival of 27%. T status
(P=.000) and adjuvant chemoradiotherapy (P=.001) were independent predictors of long-term survival. Survival advantage was
seen in T3N+ve disease (P=.007) with extended procedures. Complete (R0) resection was attained in 30 patients with a 5-year
survival advantage of 30% as compared with incomplete (R1) resection (P=.0002). Adjuvant chemoradiotherapy improved survival
in simple cholecystectomy group (P=.0008) but no advantage was seen after extended procedures. Stage III (P=.001) and node-positive
disease (P=.0005) had significant benefit with adjuvant therapy. Poor differentiation and vascular invasion were associated
with poor long-term survival. R0 resection was associated with prolonged survival. Extended procedures improved survival in
patients with T3N+ve disease. Addition of chemoradiotherapy made significant improvement in long-term survival in stage III
and node-positive lesions and in patients undergoing simple cholecystectomy. R0 resection predicted long-term survival in
gall bladder cancer. T3 N+ve disease had better survival after extended procedures. Adjuvant chemoradiotherapy improved survival
in stage III and node-positive disease. Poor differentiation and vascular invasion were adverse predictors of survival. 相似文献
34.
Robert A. Mischkowski Max J. Zinser Alexander C. Kübler Barbara Krug Ulrich Seifert Joachim E. Zller 《Journal of cranio-maxillo-facial surgery》2006,34(8):478-483
BACKGROUND: An augmented reality tool for computer assisted surgery named X-Scope allows visual tracking of real anatomical structures in superposition with volume rendered CT or MRI scans and thus can be used for navigated translocation of bony segments. METHODS: In a feasibility study X-Scope was used in orthognathic surgery to control the translocation of the maxilla after Le Fort I osteotomy within a bimaxillary procedure. The situation achieved was compared with the pre-operative situation by means of cephalometric analysis on lateral and frontal cephalograms. RESULTS: The technique was successfully utilized in 5 patients. Maxillary positioning using X-Scope was accomplished accurately within a range of 1mm. The tool was used in all cases in addition to the usual intra-operative splints. A stand-alone application without conventional control does not yet seem reasonable. CONCLUSION: Augmented reality tools like X-Scope may be helpful for controlling maxillary translocation in orthognathic surgery. The application to other interventions in cranio-maxillofacial surgery such as Le Fort III osteotomy, fronto-orbital advancement, and cranial vault reshaping or repair may also be considered. 相似文献
35.
PTEN及Bcl-2蛋白在膀胱移行细胞癌中的表达及其意义 总被引:1,自引:0,他引:1
目的:探讨PTEN及Bcl-2蛋白在膀胱移行细胞癌的表达规律及其临床意义。方法:应用免疫组织化学链亲和素-生物素-霉复合物(SP)方法检测43例膀胱移行细胞癌和7例正常黏膜组织中PTEN及Bcl-2蛋白的表达.分析二者的表达与膀胱癌病理参数的关系。结果:(1)G1、G2、G3肿瘤PTEN表达阳性率分别为85.7%、80.4%、73.3%,浸润性肿瘤和表浅性肿瘤表达阳性率分别为70.4%和93.8%,说明PTEN表达阳性率与肿瘤病理分级、临床分期有关。(2)G。、G2、G3肿瘤Bcl-2表达阳性率分别为14.2%、57.14%、66.67%,浸润性肿瘤和表浅性肿瘤表达阳性率分别为59.3%和43.8%,说明Bcl-2表达阳性率与肿瘤病理分级、临床分期有关。(3)随着肿瘤恶性程度的增高和临床分期进展,PTEN蛋白阳性率呈下降,Bcl-2表达呈增高趋势,二者表达呈负相关关系。结论:PTEN的抑癌作用可能与Bcl-2有关.二者的异常表达在膀胱移行细胞癌的发生、发展过程中起重要作用。二者同时检测有助于判断预后。 相似文献
36.
37.
肾移植术后并发尿路上皮肿瘤的临床分析 总被引:8,自引:0,他引:8
目的 分析肾移植患者并发尿路上皮肿瘤的特点,探讨其诊治方法。方法 自1998~2003年肾移植患者1293例,术后发生尿路上皮恶性肿瘤21例(1.6%)。男4例,女17例。17例原发病为慢性问质性肾炎。发生尿路上皮肿瘤距肾移植6~62个月,平均26个月。其中膀胱癌6例,单侧肾盂或输尿管癌6例,单侧肾盂或输尿管、膀胱癌8例,双侧肾盂输尿管癌1例。10例上尿路肿瘤发生部位与移植肾同侧,4例发生于移植肾对侧。临床症状以无痛性肉服血尿和反复泌尿系感染为主。19例行手术治疗,术后所有患者免疫抑制剂用量减少1/3并辅以局部灌注化疗。结果 2例行姑息性治疗的晚期肿瘤患者分别于发现肿瘤5、8个月死亡。余19例现已随访2~5年。13例肿瘤复发,复发部位为膀胱或对侧原。肾、输尿管。所有患者在免疫抑制剂减量期间均未出现急性排斥。2例因切除移植肾恢复透析,17例肾功能正常。结论 慢性间质性。肾炎导致。肾功能衰竭的。肾移植患者和女性肾移植患者易发生移植后尿路上皮肿瘤;移植肾同侧上尿路较对侧好发肿瘤;对移植肾对侧为首发的上尿路发生肿瘤者可预防性行双侧上尿路根治性切除。 相似文献
38.
Eimear Kieran 《Current Obstetrics & Gynaecology》2006,16(4):218-225
39.
Excretory/secretory antigen of Toxocara canis: recognition profiles of polyclonal and larvicidal monoclonal antibodies 总被引:1,自引:1,他引:0
Summary Five monoclonal antibodies against the excretory/secretory (E/S) antigen of Toxocara canis were obtained and characterized. Immunoprecipitating activity was demonstrated in an in-vitro micropre-cipitating assay using live T. canis larvae. Their capacity to kill larvae was also shown in an in-vitro assay. Two zones of reactivity were observed in 7.5 and 12.5% SDS-PAGE (177-77 kD, 43-15 kD) of immunoprecipitates of human and mouse positive polyclonal anlisera. The murine monoclonal antibodies showed a common pattern of reactivity with the proteins in the 177-77 kD range. 相似文献
40.
Olle Zetterström Christer Andersson Leif Eriksson ers Fredriksson Johan Friskopp Gunnar Heden Bernt Jansson Tord Lundgren Rolf Nilveus ers Olsson Stefan Renvert Lars Salonen Lars Sjöström ers Winell ers Östgren Stina Gestrelius 《Journal of clinical periodontology》1997,24(9):697-704
Abstract The aim of the present clinical trial was to test tolerability during 2 treatments with EMDOGAIN® in a large number of patients. An open, controlled study design in 10 Swedish specialist clinics was chosen, with a test group of 107 patients treated with EMDOGAIN® in connection with periodontal surgery at 2 surgical test sites per patient. The procedures were performed 2 to 6 weeks apart on one-rooted teeth with at least 4 mm deep intraosseous lesions. A control group of 33 patients underwent flap surgery without EMDOGAIN® at I comparable site. In total 214 test and 33 control surgeries were performed. Serum samples were obtained from test patients for analysis of total and specific antibody levels. 10 of the patients had samples taken before and after the first surgery. 56 other samples were taken after one treatment with EMDOGAIN®, and 63 after 2 treatments. None of the samples, not even from allergy-prone patients after 2 treatments, indicated deviations from established baseline ranges. This indicates that the immunogenic potential of EMDOGAIN® is extremely low when applied in conjunction with periodontal surgery. Comparison between the test and control groups demonstrated the same type and frequency of post-surgical experiences, i.e., reactions caused by the surgical procedure itself. Clinical probing and radiographic evaluation was performed at baseline and 8 months postsurgery. About half of the patients (44 test and 21 control) were also evaluated after 3 years. There was a significant difference between the test and control results at 8 months post surgery. and this difference had increased further at the 3 year follow-up. The 2.5–3 mm increase in attachment and bone level after treatment with EMDOGAIN® was of the same magnitude as seen in the studies with split-mouth design aiming for lest of effectiveness of EMDOGAIN®. 相似文献